Alchemia teams with Merck Serono for cancer trial
22 May, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has announced a collaborative trial of HA-Irinotecan with Merck Serono’s Erbitux and blamed seasonal factors for falling quarterly fondaparinux sales.
Industry Innovation Precincts applications open
21 May, 2013As part of the federal government’s Innovation and Industry Policy ‘A Plan for Australian Jobs’, released in February, applications have opened for up to eight Industry Innovation Precincts.
Agreement signed between Garvan, Cancer Therapeutics CRC and SYNkinase
20 May, 2013The development of a new research tool for proteomics and chemical biology is set to move forward.
New spin-out company to develop nanoparticle drugs
16 May, 2013A new spin-out company has been set up by the University of Western Australia to commercialise nanoparticle drugs for biomedical applications.
Revised code to benefit ASX-listed life science companies
16 May, 2013The Minister for Technology, the Hon Gordon Rich-Phillips, yesterday joined forces with the Australian Securities Exchange (ASX) and Australia’s biotechnology industry association, AusBiotech, to launch a revised edition of the industry code of best practice that will support capital formation by ASX-listed life science companies.
REVA appoints new managing director
15 May, 2013 by Dylan Bushell-EmblingMichel Vanbrabant will joint REVA Medical (ASX:RVA) as managing director to help the company prepare its EU market strategy for bioresorbable coronary scaffold ReZolve2.
pSivida posts $2.8m loss for Q3
15 May, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) says its net loss grew slightly in Q3, as it awaits revenue and royalty payments from partner Alimera for the Iluvien insert.
Phosphagenics and US agency target cow infection
15 May, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) and a US Department of Agriculture research agency will jointly formulate and test products aimed at fighting the bacterial infection mastitis in dairy cows.
Bioniche to sell animal health division
14 May, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has hired an adviser to help it negotiate a sale of its animal health division and has received two preliminary partnership offers for bladder cancer treatment Urocidin.
Mercury Capital invests in Novotech
14 May, 2013 by Dylan Bushell-EmblingPE firm Mercury Capital has acquired a 30% stake in incumbent Australian CRO Novotech, with the option to increase its holding to 50%.
AusBiotech secures Australian first with world brain mapping congress
14 May, 2013AusBiotech is pleased to announce that the 11th Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT) will be held in Australia for the first time in March 2014.
AU boffins develop bacteria-killing Trojan horse
13 May, 2013 by Dylan Bushell-EmblingScientists from UOW and UNSW have patented a new drug technology for combating antibiotic-resistant bacteria, developed by thinking like the enemy.
Starpharma dendrimer effective against adenovius
13 May, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) said its lead dendrimer candidate has shown potential as the first treatment for adenovirus, the primary cause of viral conjunctivitis.
BioDiem moves to animal trials in pneumocystosis
13 May, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has said its antimicrobial candidate BDM-I is ready for preclinical trials against Pneumocystosis, a parasitic fungus that can cause pneumonia.
Cellmid to buy Advangen Japan in $4m deal
10 May, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) will pay around $4m in cash and stock to acquire Advangen Japan and, with it, the hair growth technology platform behind Cellmid’s evolis line.
